Radna skupina za mijelodisplastični sindrom Hrvatske kooperativne grupe za hematološke
bolesti (KROHEM), Referalni centar Ministarstva zdravlja Republike Hrvatske za …

Although allogeneic transplantation has resulted in long-term disease-free survival in some
patients with myelodysplastic syndromes (MDS), the morbidity and mortality of this approach …

High-risk myelodysplastic syndrome (MDS) patients have usually a less favorable outcome
after intensive treatment compared with de novo acute myeloid leukemia (AML) patients …

The primary objective of this trial was to assess the feasibility, toxicity profile, and antitumor
activity of gemtuzumab ozogamicin (GO) combined with a chemotherapy remission …

Myelodysplastic syndromes (MDS) are a group of common bone marrow disorders
characterized by ineffective hematopoiesis, peripheral cytopenias, and a propensity for …

Participation in clinical trials may allow patients with MDS to gain access to therapies not
otherwise available. However, access is limited by strict inclusion and exclusion criteria …

Treatment planning for patients with MDS who are HCT candidates should comprise the
entire treatment arc including pre-HCT debulking, possibly with hypomethylating agents …

Between 30 and 50% of patients with acute myeloid leukaemia (AML) relapse after
autologous stem cell transplantation (ASCT). One possibility of reducing the relapse rate …

Haematopoietic stem cell transplantation (HSCT) is now an established treatment fora
number of non-malignant and malignant conditions. Bone marrow-or peripheral blood …

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for
patients with myelodysplastic syndromes (MDSs). We have analyzed the outcome of 81 …